Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.

Huynh, Lynn; Hass, Steve; Peyrin-Biroulet, Laurent; Duh, Mei Sheng; Sipsma, Heather; Cheng, Mu; Lax, Angie; Nag, Arpita

Huynh, Lynn; Hass, Steve; Peyrin-Biroulet, Laurent; Duh, Mei Sheng; Sipsma, Heather; Cheng, Mu; Lax, Angie; Nag, Arpita.

Afiliación

Huynh L; Analysis Group, Inc., Boston, Massachusetts, USA.
Hass S; H. E. Outcomes, LLC, Los Angeles, California, USA.
Peyrin-Biroulet L; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Nancy, France.
Duh MS; Analysis Group, Inc., Boston, Massachusetts, USA.
Sipsma H; Analysis Group, Inc., Boston, Massachusetts, USA.
Cheng M; Analysis Group, Inc., Boston, Massachusetts, USA.
Lax A; Analysis Group, Inc., Boston, Massachusetts, USA.
Nag A; Takeda Development Center Americas, Lexington, Massachusetts, USA.

Crohns Colitis 360 ; 4(1): otac001, 2022 Jan.

Article en En | MEDLINE | ID: mdl-36777550

Palabras clave

Crohn's disease; biological therapy; biosimilar pharmaceuticals; physicians' practice patterns; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Crohns Colitis 360 Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google